Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Astellas and Bristol-Myers Squibb
Acute myeloid leukemia (AML) is a cancer of the myeloid line of
blood cells, characterized by the rapid growth of abnormal white
blood cells that build up in the bone marrow and interfere with the
production of normal blood cells. AML is the most common acute
leukemia affecting adults, and its incidence increases with age.
Although AML is a relatively rare disease, accounting for roughly
1.2% of cancer deaths in the United States, its incidence is
expected to increase as the population ages. The American Cancer
Society estimates that there were approximately 21,380 new cases of
AML and 10,590 deaths from AML in the United States in 2019. The
five-year survival rate has not improved in older patients despite
of 40 years of research. Fortunately for patients with AML, many new
treatments are are now here or are on the horizon. New options,
which have the ability to target certain types of mutations, have
been approved in AML for the first time since 1990. With so many new
options becoming available in the next few years, the treatment
paradigm in AML, especially in relapsed or refractory disease, is
set to drastically change. With that change comes a knowledge gap
among physician medical directors, oncologists, practicing
physicians and nurses. For this reason, it is critical that these
HCPs are educated and updated on these emerging options and
strategies for their implementation into the treatment paradigm,
which will ultimately improve patient outcomes in the AML patient
AML has several subtypes and treatment and prognosis vary among
subtypes. After AML has been diagnosed, tests are done to find out
the subtype. This is especially important, as several new treatments
focus on AML disease with certain mutations, including FLT3.
Following older treatment paradigms, AML has been cured in 35-40% of
people under 60 years old, but only in 5-15% of people over 60 years
old. Fortunately for patients with AML, that treatment paradigm has
begun to dramatically change, as novel targeted agents have shown
improved efficacy and safety outcomes in recent clinical data. It is
imperative that physician medical directors, oncologists, practicing
physicians, nurse case managers and other healthcare professionals
are brought up to date regarding this new data in these novel
treatments, as one has already become available and more options are
set to follow.
Upon completion of this
activity, participants will be able to:
Examine the clinical and economic
burden of acute myeloid leukemia (AML), including factors that
contribute to poor prognosis and increased costs
Analyze the efficacy, safety and
mechanisms of action of novel therapeutics in AML in a range of
Explore the evolving role of
maintenance therapy for patients with AML in first remission
Examine the role of mutation
analysis in appropriate patient selection for targeted treatment
Interpret recent clinical trial data
evaluating the efficacy and safety of treatments targeting FLT3,
IDH1/2, and BCL-2
Employ interventions such as
clinical pathways and site of care initiatives for optimal cost
management and improved outcomes in AML
||Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
serves as a consultant for AbbVie, Agios, Amgen,
Astellas, Blueprint, Celgene/BMS, Kura, Pfizer, Seattle
Genetics, Takeda, and Trillium. He has received
grant/research support from Agios and Celgene/BMS. His
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
Astellas and Bristol-Myers Squibb
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue